Hepatocellular Carcinoma Clinical Trials in Detroit, Michigan
9 recruitingDetroit, Michigan
Showing 1–9 of 9 trials
Recruiting
Phase 1
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Solid Tumor+7 more
Exelixis1,314 enrolled122 locationsNCT05176483
Recruiting
Phase 2
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
Hepatocellular Carcinoma
Genentech, Inc.30 enrolled61 locationsNCT06096779
Recruiting
Phase 1
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Gastric CancerEndometrial CancerHepatocellular Carcinoma+5 more
Seagen, a wholly owned subsidiary of Pfizer714 enrolled61 locationsNCT05208762
Recruiting
Phase 3
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
Stage III Hepatocellular Carcinoma AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8Advanced Hepatocellular Carcinoma
NRG Oncology252 enrolled83 locationsNCT07166406
Recruiting
Phase 3
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
Hepatocellular Carcinoma
AstraZeneca1,220 enrolled204 locationsNCT06921785
Recruiting
Not Applicable
TheraBionic P1 Device in Subjects With Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma Recurrent
Barbara Ann Karmanos Cancer Institute198 enrolled6 locationsNCT07118202
Recruiting
Phase 1
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
Solid TumorsMetastatic Hepatocellular CarcinomaAdvanced Solid Tumors+11 more
Tyra Biosciences, Inc100 enrolled16 locationsNCT06915753
Recruiting
Phase 1Phase 2
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
Hepatocellular Carcinoma
Tvardi Therapeutics, Incorporated178 enrolled21 locationsNCT05440708
Recruiting
Phase 2Phase 3
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma
AbbVie660 enrolled37 locationsNCT06109272